The Power of Proteomics is a three-day Thermo Fisher Scientific virtual event that focuses on harnessing the power of omics to advance scientific research. The virtual event will feature a series of presentations, followed by roundtable discussions, from academia and industry-leading experts.
Sessions will include:
In addition to the presentations, audiences can also visit our five virtual booths, where Thermo Fisher Scientific experts will be there to welcome you (virtually) and answer any questions you may have. There will also be a dedicated poster hall and the networking lounge where you can converse with other participants too!
More speakers added daily!
Dr. Ryan Bomgarden received his bachelor’s degree from Coe College with majors in Chemistry and Molecular Biology before completing his Ph.D. at Stanford University under Dr. Karlene Cimprich where he worked on biochemical characterization of the checkpoint kinase ATR DNA binding activity and signaling in UV-sensitive human cell lines.
In 2005, Dr. Bomgarden joined Pierce Biotechnology, now part of Thermo Fisher Scientific, where he has led the development of over a 100 new products including Tandem Mass Tag reagents for relative quantitation of proteomic samples, protein digest standards for LC-MS quality control, MS-cleavable crosslinkers for protein structure analysis, Heavy Protein in-vitro translation kits for production of stable isotope-labeled proteins; and ActivX Probes for enzyme inhibitor profiling and detection. Currently, Dr. Bomgarden is a Senior Manager of the Mass Spec Reagent group based in Rockford, IL.
In addition to his work at Thermo Fisher Scientific, Dr. Bomgarden is also an adjunct professor at the University of Illinois College of Medicine where he teaches courses on biochemical techniques, drug design and ethics. Dr. Bomgarden is also heavily involved in STEM education, creating and performing science demonstrations for local non-profit organizations and as a coach for the Winnebago Middle School Science Olympiad team.
Max read Biochemistry at the University of Oxford as an undergraduate and, after doctoral studies at Oxford and Scripps Research, went on to run the Glycoprotein Therapeutics Laboratory within Oxford’s Department of Biochemistry. Max moved to the University of Southampton in 2017 where he is Professor of Glycobiology. His laboratory operates at the nexus of glycoprotein engineering and glycan analytics and is currently dedicated to the design and analysis of the glycoprotein-based therapies and vaccines. Max’s laboratory is funded by the Bill & Melinda Gates Foundation through the Collaboration for AIDS/Vaccine Discovery, the International AIDS Vaccine Initiative, the US National Institute of Health, the European Union Horizon 2020 programme, and by Against Breast Cancer. He is currently a Supernumerary Fellow at Oriel College, Oxford, and Professor Adjunct in the Department of Immunology and Microbiology at Scripps Research.
Tiannan received training of clinical medicine in Tongji Medical College, Huazhong University of Science and Technology (1999-2006), and biology in Wuhan University (2001-2005), before he moved to Singapore for PhD training in cancer proteomics in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr.Oi Lian Kon in National Cancer Centre Singapore (2008-2012). In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. In March 2017, Tiannan relocated to ProCan, Children’s Medical Research Institute, The University of Sydney as the Scientific Director. Since August 2017, he became a Tenure Track Assistant Professor in Westlake University, Hangzhou, China. The Guo lab (www.guomics.com) focuses on advancing proteomics technologies for clinical cohort studies.
Dr. Andreas FR Hühmer is currently the Marketing Director for all things ‘Omics’ at Thermo Fisher Scientific in San Jose, CA. In his current role, he directs the day-to-day marketing business as well as the long-term strategy for the business. He collaborates closely with colleagues in product marketing within the business unit and across the division to deliver innovative and enabling solutions to customers. In a previous role, Dr. Hühmer was instrumental in commercializing the ProteomeX ion trap product, the first highly integrated turn-key solution for Mudpit experiments. He also was responsible for the development of the next generation biosoftware products, such as Proteome Discoverer and SIEVE. Dr. Hühmer holds a PhD (1997) and a Master of Science degree (1996) in Pharmaceutical Chemistry from the University of Kansas. He also received a Bachelor of Science degree (1991) and a Master of Science degree (1993) in Analytical Chemistry from the Free University of Berlin, Germany.
Lihua Jiang is trained in medicine and received her Ph.D. in Analytical Chemistry from Dr. Neil Kelleher’s lab in University of Illinois at Urbana-Champaign. After graduation, she worked in Thermo as an application scientist for about two years. When Dr. Michael Snyder, a world-renowned scientist in genomics, transferred from Yale to Stanford, she decided to join force with him in the emerging field of personalized medicine using Omics technology. In Dr. Snyder’s Lab, she built the platform for both proteomics and metabolomics and published her work in the integrated Personal Omics Profiling (iPOP) paper in Cell (2012). In the past a few years, she led the quantitative proteomics study of the normal human tissues as part of the Genotype-Tissue Expression (GTEx) projects. Her work is just published in Cell. She now directs the Mass Spectrometry Center for Advanced Research in the department of Genetics. She is an expert in mass spectrometry technologies and truly believes that the integration of modern technologies with omics profiling will revolutionize medicine.
Neil L. Kelleher, PhD, is the Walter and Mary Glass Professor of Molecular Biosciences and Professor of Chemistry in the Weinberg College of Arts and Sciences. He also is Director of the Proteomics Center of Excellence and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He has successfully driven technology development and applications of very high performance mass spectrometry in the areas of top down proteomics, natural products discovery, and cancer biology and has over 350 publications, with an H-factor of 70 and more than 1800 citations/year. His outstanding contributions to the fields of proteomics and natural products chemistry have been recognized by multiple awards, including the Biemann Medal from the American Society for Mass Spectrometry, the Pfizer Award in Enzyme Chemistry from the American Chemical Society, the Presidential Early Career Award in Science and Engineering, the Camille Dreyfus Teacher-Scholar Award, a Sloan Fellowship, a Packard Fellowship, and an NSF CAREER Award.
Bernhard Kuster is a chemist by training and obtained is PhD in Biochemistry from the University of Oxford. He did a PostDoc funded by an EMBO long-term fellowship at the EMBL in Heidelberg and the University of Southern Denmark in Odense. After seven years as VP Analytical Sciences and Informatics at the biotech firm Cellzome (now GSK), he became Full Professor and Chair of Proteomics at the Technical University of Munich in 2007. Bernhard is a Carl von Linde Senior Fellow of the TUM Institute for Advanced Study and has received a number of awards in recognition of his contributions to science, including the Discovery in Proteomic Sciences Award of HUPO. His team of biochemists and bioinformaticians was recently awarded an ERC Advanced Grant to research how cancer drugs actually work. Bernhard has also co-founded two start-up companies that operate in the area of proteomics and artificial intelligence.
Janne Lehtiö holds faculty professor position in Medical Proteomics at Karolinska Institutet, Stockholm, Sweden and since 2018 he has devoted part of his time as Scientific Director at Science for Life Laboratory, Swedish national laboratories for biosciences. Since 2020, Lehtiö is also serving in board of directors for Karolinska Comprehensive Cancer Center. Prior that he has been principle investigator at Dept. of Oncology and Pathology at Karolinska Institutet and since 2006, Dr. Lehtiö was appointed as director of the Karolinska University Hospital’s clinical proteomics facility. His educational background includes MSc on biochemistry in Helsinki University, Finland and PhD in engineering in Royal Institute of Technology in Stockholm, Sweden. Post the PhD, Lehtiö worked few years in biotech industry in USA and Europe; and obtained postdoctoral experience in in cancer research at Karolinska Institutet. In 2009, Lehtiö got his assistant professor (docent) merit at Karolinska Institutet. Dr Lehtiö’s major research interest is to improve human proteome analysis with the main application focus on precision cancer medicine. The Lehtiö has 130 peer reviewed original publication and together with his group, has published number of novel methods for proteome analysis, data-analysis and cancer research applications in leading journals. The main cancer types that the group focuses are lung and breast cancer as well as on a newly started program on particular childhood and adult leukaemia. Lehtiö has also vast experience on research infrastructures, leading core facilities and national infrastructure initiatives; and was selected as one of the national research infrastructure fellows (including 15 mSEK grant) by The Swedish Foundation for Strategic Research. Moreover, Lehtiö is a co-founder of a biotech company Fenomark Diagnostics. Janne Lehtiö has supervised 15 PhD students and 17 postdoctoral fellows. Lehtiö has a formal university teacher education and is currently lecturing in four graduate programs at KI and frequent lecturer at Swedish universities.
Daniel Lopez-Ferrer is senior manager leading the Proteomics Vertical Marketing team, at Thermo Fisher Scientific. In his current role, Daniel and his team are focused on the identification and development of new proteomics analytical tools and applications that bring broad benefits to the biosciences community. He has held positions as a Senior Scientist at Caprion Proteomics (CA, USA) and Pacific Northwest National Laboratory (WA, USA) developing technologies for high-throughput, large-scale proteomics projects. Dr. Lopez-Ferrer has over 35 peer review papers and several patents.
The major research foci of György Marko-Varga are clinical studies, drug characterisation within cancerous disease and biobanking. The Marko-Varga research group holds >40 scientists. In 2016, the Obama administration and the NIH launched the Cancer Moonshot initiative led by the 47th U.S. Vice President Joe Biden. In 2017, Marko-Varga was appointed the head of the European Cancer Moonshot Center located at Lund University in Sweden. The European hub is aligned with 15 medical centres; in Southern Sweden (10 hospitals), across Europe and Asia. In addition to front-lining cancer research in Europe, Marko-Varga was also responsible for the IRESSA (Gefitinib) and IPASS protein biomarker discovery studies in Japan (2005-2012). The program included 52 lung cancer clinical centres throughout Japan, China, and South Korea. Involving 9,000 patients, this program was the largest ever biomarker study in the field of cancer research. More recently, he was also responsible for biobanking and biomarker developments in the ‘Big 3’ study (2014-2021), with 8,000 patients recruited, where close to 3 million samples were processed so far.
Collectively, the established clinical and technological infrastructure, the recruited scientific research team, the collaborations within the pharmaceutical industry, and the connections with oncology centres in Europe and Asia has elevated Marko-Varga to be one of the paramount cancer researchers in Europe and internationally.
Dr Matthews gained his PhD from St Andrews University, UK studying adenovirus protein-protein interactions before going to work on adenovirus based gene therapy vectors at McMaster University in Ontario, Canada. He returned to the UK to work on herpesvirus based gene therapy vectors before securing a lectureship in virology at the University of Bristol. Here he returned to work on adenoviruses studying how adenovirus affects the nucleolar proteome and how the use of next generation transcriptomics can be used to inform a deeper understanding of proteomics and host cell changes in response to viral infection. He has since worked on a number of zoonotic viral diseases including Hendra virus, Ebola, MERS-CoV and currently SARS-CoV-2.
Valdemir Melechco Carvalho received his Ph.D. in Biochemistry from the University of São Paulo. He joined Fleury Group in 2001 where he is a Senior Scientist and leads a team focused on the development of applications of chromatography and mass spectrometry to clinical analysis. He is also a professor at the Clinical and Toxicology Sciences graduate program at the Pharmaceutical Sciences School of the University of São Paulo.
Lukas graduated from ETH Zurich in molecular biology. For his PhD, he joined the groups of geneticist Michael Hengartner and proteomics pioneer Ruedi Aebersold and received his degree in 2009 from the University of Zurich. After that Lukas joined Biognosys in 2010 as one if its first employees. As CTO, he oversees research as well as product and workflow development at Biognosys.
Dr. Erwin Schoof heads the DTU Proteomics Facility while pursuing an academic career in cancer stem cell biology. He holds an appointment as Associate Professor at DTU, focusing on cell heterogeneity within normal and malignant hematopoiesis.
Lauren received her B.S. in Biomedical Engineering at the University of Wisconsin-Madison in 2015 and is currently finishing her Bioengineering PhD at MIT in Forest White’s lab. Her research focuses on developing and applying novel quantitative mass spectrometry methods in the fields on antigen presentation and phosphorylation signaling dynamics, with the goal of gaining unique biological insights across cancer types.
Danielle Swaney obtained her PhD in analytical chemistry in the laboratory of Joshua Coon at the University of Wisconsin, where she focused on methods developments in the areas of phosphoproteomics and electron transfer dissociation. She then spent 4 year as a post-doctoral fellow at the University of Washington in the lab of Judit Villen, where she develop approaches to study post-translational modification crosstalk. In 2015, Danielle joined as a faculty member at UCSF, where she has worked in close collaboration with the lab of Nevan Krogan to apply proteomics towards the study of host-pathogen biology.
Dr. Nicola Ternette trained in Physics and Biochemistry at the Universities of Bonn, Greifswald and Bochum in Germany. She pursued her post-graduate studies in developing and evaluating DNA vaccines for Respiratory Syncytial Virus (RSV) at the Institute for Molecular and Medical Virology in Bochum. Following her PhD, she continued her research on viral infection at the University of Oxford. She specialized in sequencing of HLA-associated peptidomes using nanoflow ultra-performance liquid chromatography tandem mass spectrometry (LC-MS) with the focus on identification of viral antigens for the development of T cell vaccines for HIV-1. Since 2015, she is heading the Antigen Discovery Group at Oxford. Her group has expanded their expertise to deep sequencing of immunopeptidomes in multiple pathogen infection models, analysis of the antigenic landscape of solid tumours and haematological cancers and characterisation of antigens involved in autoimmune diseases.
Mathias Wilhelm is a trained bioinformatician but generally intrigued by all mechanisms which require a good understanding of mathematics, physics, chemistry and biology. Initially working in the field of metabolomics, he spent the last 7 years of his scientific career focusing on studying the life-cycle of proteins using mass spectrometry. Today, he leads a small group of bioinformaticians at the Chair of Proteomics and Bioanalytics (Prof. Bernhard Kuster, Technical University Munich) and is interested in supporting wet-lab scientists by developing tools for data analysis, integration, interpretation and dissemination. In addition, he is a co-founder of OmicScouts GmbH and MSAID GmbH, both providing services in the field of mass spectromtery-based proteomics.
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events